Nvidia and TSMC to unveil first domestic wafer for Blackwell chips, Axios reports
Troy Wichterman, Chief Financial Officer of BioLife Solutions Inc (NASDAQ:BLFS), sold 833 shares of common stock on October 9, 2025, at a price of $27.36, for a total transaction value of $22,790. Following the transaction, Wichterman directly owns 183,353 shares of BioLife Solutions. The company, currently valued at $1.33 billion, has shown impressive revenue growth of 68% over the last twelve months and maintains a strong liquidity position with a current ratio of 4.43. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which was adopted on January 3, 2023, to cover tax obligations related to the vesting of restricted stock. With a beta of 1.95 and trading near its 52-week high, BLFS shows considerable price volatility. For deeper insights into BioLife Solutions’ financial health and growth prospects, InvestingPro offers 8 additional key tips and a comprehensive Pro Research Report.
In other recent news, BioLife Solutions reported its second-quarter 2025 earnings, revealing a notable revenue increase of 29% year-over-year, reaching $25.42 million, which exceeded expectations. Despite the revenue growth, the company posted a net loss of $15.8 million, or $0.33 per share, which was larger than anticipated due to a $15.5 million in-process R&D expense related to the PanTHERA transaction. Additionally, BioLife Solutions announced the sale of its cold chain logistics subsidiary, SAVSU Cleo Technologies, to Peli BioThermal for $25.5 million in cash. Analyst firm H.C. Wainwright responded by raising its price target for BioLife Solutions to $32 from $30, while maintaining a Buy rating. KeyBanc also reiterated its Overweight rating on the company, citing potential growth avenues and a long-term revenue target. During its 2025 annual meeting, shareholders re-elected all director nominees and approved executive compensation and auditor appointments. These developments reflect a mix of strategic moves and financial challenges for BioLife Solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.